BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 21550694)

  • 21. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
    Kamijo H; Miyagaki T
    Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas.
    Whittaker SJ; Marsden JR; Spittle M; Russell Jones R; ;
    Br J Dermatol; 2003 Dec; 149(6):1095-1107. PubMed ID: 14696593
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
    Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
    J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis.
    Stoll JR; Willner J; Oh Y; Pulitzer M; Moskowitz A; Horwitz S; Myskowski P; Noor SJ
    J Am Acad Dermatol; 2021 Nov; 85(5):1073-1090. PubMed ID: 33940098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rare variants of cutaneous T-cell lymphomas].
    Goerdt S; Trautmann C; Kütting B; Ramaker J; Schmuth M; Thiel E; Luger T; Stein H; Orfanos CE
    Hautarzt; 1996 Feb; 47(2):96-105. PubMed ID: 8868452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A new nail in the CTCL coffin.
    Lessin SR
    J Invest Dermatol; 2006 Nov; 126(11):2368-9. PubMed ID: 17041618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current therapy concepts in cutaneous T-cell lymphomas].
    Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
    Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
    Hughes CF; Newland K; McCormack C; Lade S; Prince HM
    Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Total body-surface area as a new prognostic variable in mycosis fungoides and Sézary syndrome.
    Novelli S; García-Muret P; Mozos A; Sierra J; Briones J
    Leuk Lymphoma; 2016 May; 57(5):1060-6. PubMed ID: 27096891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.
    Ghazawi FM; Netchiporouk E; Rahme E; Tsang M; Moreau L; Glassman S; Provost N; Gilbert M; Jean SE; Pehr K; Sasseville D; Litvinov IV
    Cancer; 2017 Sep; 123(18):3550-3567. PubMed ID: 28493286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycosis fungoides and Sézary syndrome.
    Jonak C; Tittes J; Brunner PM; Guenova E
    J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Local radiation for cutaneous T-cell lymphoma other than mycosis fungoides and Sézary syndrome.
    Shikama N
    Chin Clin Oncol; 2019 Feb; 8(1):8. PubMed ID: 30180750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
    Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
    Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
    Beltraminelli H
    Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Controversies in the management of the cutaneous T cell lymphomas.
    Zic JA
    Dermatol Ther; 2009; 22(5):407-17. PubMed ID: 19845718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
    Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
    Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
    Berg S; Villasenor-Park J; Haun P; Kim EJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.
    Danish HH; Liu S; Jhaveri J; Flowers CR; Lechowicz MJ; Esiashvili N; Khan MK
    Leuk Lymphoma; 2016 Dec; 57(12):2813-2819. PubMed ID: 27104864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.